Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease

BACKGROUND: Intravenous immunoglobulin (IVIg) treatment results in an effective response from patients with acute-phase Kawasaki disease (KD), but 16.5% of them remain nonresponsive to IVIg. To address this therapeutic challenge, we tried a new therapeutic drug, mizoribine (MZR), in a mouse model of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Takahashi, Kei, Oharaseki, Toshiaki, Nagao, Tomokazu, Yokouchi, Yuki, Yamada, Hitomi, Nagi-Miura, Noriko, Ohno, Naohito, Saji, Tsutomu, Okazaki, Tomio, Suzuki, Kazuo
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2011
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3239324/
https://ncbi.nlm.nih.gov/pubmed/21958311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1546-0096-9-30
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars